The great rush of labs towards RNA vaccines

After the success of Moderna and Pfizer / BioNtech, all public and private groups want their messenger RNA (mRNA) vaccine against Covid-19.

The approach is all the more promising as these vaccines seem to protect well against the so-called Brazilian variant (P.1) and, with a slightly lower but nevertheless good efficacy, against the so-called South African variant (B.1.351) .

And this remarkable efficacy does not appear to be accompanied by serious side effects, unlike the vaccines from AstraZeneca and Janssen / Johnson & Johnson.

To discover

• Test, isolation: the procedure to follow in the event of a suspicion of Covid-19

• Covid-19: instructions for use of self-tests

Clinical tests

While many did not believe it a few months ago, now

“every major pharmaceutical group wants its mRNA vaccine.

About fifteen players have already announced projects ”,

identifies Bernard Verrier, CNRS research director at the Institute of Protein Biology and Chemistry.

The French Sanofi, allied with the American Translate Bio, launched its clinical trials on March 12, which are due to end in the third quarter.

In addition, at the end of March, the first

This article is for subscribers only.

You have 70% left to discover.

Subscribe: 1 € the first month

Can be canceled at any time

I ENJOY IT

Already subscribed?

Log in